What the 2026 quota order covers
The quota order sets annual aggregate production quotas for controlled substances and annual needs for certain listed chemicals. The 2026 final order is effective January 5, 2026.
Aggregate production quotas are the ceiling for how much of a drug class may be produced in the United States in a calendar year for medical, scientific, research and industrial needs, export needs and reserve stocks. Imports are handled through separate approvals and the aggregate quota table does not automatically cover every import scenario, so your supply plan should treat domestic production and imports as distinct tracks.
For psilocybin research, the key numbers in the 2026 order are the aggregate caps for the basic classes psilocybin and psilocyn, expressed in grams. The 2026 order sets psilocybin at 50,000 grams and psilocyn at 80,000 grams. The order also notes that these two caps were set higher than the proposed levels after a request during the public process.
